Rhythm Biotherapeutics Inc. (RBI) is a pre-clinical spinout of the University of Ottawa Heart Institute, founded in November 2022 by Darryl Davis, a cardiac electrophysiologist pioneering novel therapies to prevent and cure atrial fibrillation (AF). The company has developed a patent pending exosome therapy that, in animal studies, has proven to effectively prevent postoperative atrial fibrillation (POAF). RBI’s therapy uniquely addresses atrial inflammation and fibrosis, the fundamental physiological mechanism driving POAF. RBI is currently seeking investors who will accelerate achieving its next milestones. The obtainable market in North America and Europe for POAF therapy is over US$2B per year and growing.